Navigation Links
Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
Date:6/8/2009

About Otelixizumab

Otelixizumab is a novel monoclonal antibody being developed for the treatment of type 1 diabetes and other autoimmune diseases. Otelixizumab targets CD3, a T lymphocyte receptor involved in normal cell signaling. Otelixizumab has not yet been approved for marketing. Data suggest that the antibody may work in patients with type 1 diabetes who have residual beta cells by blocking the function of effector T cells that mistakenly attack and destroy insulin-producing beta cells, while stimulating regulatory T cells that are understood to protect against effector T cell damage, thus preserving the beta cells' ability to make insulin.

About Tolerx

Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. The company's pipeline includes its lead candidate, otelixizumab, an anti-CD3 monoclonal antibody partnered with GlaxoSmithKline in Phase 3 development for the treatment of type 1 diabetes; a Phase 1 candidate, MTRX1011A, an anti-CD4 antibody that is being developed in collaboration with Genentech, Inc. for the treatment of autoimmune indications; and two pre-clinical candidates, TRX518 and TRX385, that enhance immune responses and are being evaluated for potential benefit in the treatment of cancer, chronic viral diseases, and as vaccine adjuvants. Tolerx is a privately held company headquartered in Cambridge, MA USA. For more information, please visit www.tolerx.com.


'/>"/>
SOURCE TolerRx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
2. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
3. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
4. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
9. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
10. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Originally discovered by Welfide ... Pharmaceutical Industries, Ltd) as an inflammatory drug, pranoprofen ... Pharmaceutical Co., Ltd under the trade name of ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "12th Annual ... Production" report to their offering. ... Biopharmaceutical Manufacturing Capacity and Production is the most ... organizations, current and projected future capacity and production. ...
(Date:8/28/2015)... Utah , Aug. 28, 2015  Today, in ... Prevention,s (CDC) Contact Lens Health Week, 1-800 Contacts is ... has found that contact lens wearers who do not ... greatest risk for eye infections. Most ... their lenses, but a clean lens case is sometimes ...
Breaking Medicine Technology:Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... Findings indicate early non-responders unlikely to subsequently,respond, ... benefit,from earlier change in treatment strategy, COLORADO ... data presented at the 2007 International Congress ... be assessed earlier than is presently thought, ...
... Average of More Than Two Hours Per ... 2007 /PRNewswire/ --,Adding the once daily, investigational ... to,Parkinson's patients' existing levodopa (L-dopa) therapy,significantly reduced ... activities for a longer period of time. ...
Cached Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President ... the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has served ... college expand its reach and impact through innovative technologies and strategies. , “I am ...
(Date:8/29/2015)... ... 29, 2015 , ... "I have been a licensed physical ... specialize in manual therapy, and my invention will provide headache sufferers a solution ... muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates headaches, ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau Thermale ... costs. , “Before, a threshold of $49.00 was required to qualify for free standard ... for free standard shipping for customers regardless of the item’s selling price.” , With ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... treating the localized area with stretching, soft tissue manipulation. Platelet rich plasma injections ... have shown through research to improve treatment outcomes. This localized treatment seems ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Decatur County Memorial Hospital recently transitioned management companies to partner with Wound Care ... for their outpatient wound center. , Transitioning wound care management providers can ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... Ireland, July 1 AlphaMed Press, co-publisher of the ... of stem cells and regenerative medicine, has promoted Miodrag ... Stojkovic is Deputy Director of the Prince Felipe Research ... Valencia, Spain. He led the team that first announced ...
... National Non-profit ... , ... July 1, 2009 -- This Summer, EyeCare America , has teamed up with celebrity ... eye-healthy vitamins and antioxidants. Chefs including host of the Food Network,s Quick Fix Meals with ...
... , ... is pleased to announce the Beta signup for its ground breaking 3D Workspace for ... ... -- Aftercad Software is pleased to announce the Beta signup for its ground breaking ...
... ... ... Foundation has a new ally in its fight against MS, the debilitating disease that afflicts ... neurological condition striking young adults today. The ally is Simply Shirts which is launching ...
... ... now a featured expert on searchbodydetox.com, a new informational Web site devoted to all ... ... Stephen Sinatra , a board-certified cardiologist, nutritionist, and anti-aging specialist, is now a featured ...
... Founded ... The Free Choice Foundation is a newly established grassroots organization with a core strategy ... , ... (PRWEB) July 1, 2009 -- Based on the spirit of U.S. President Obama,s ,Guarantee ...
Cached Medicine News:Health News:STEM CELLS Promotes Miodrag Stojkovic to Editor 2Health News:This Summer, EyeCare America and Celebrity Chefs Want You to Feast Your Eyes on Eye Healthy Foods 2Health News:This Summer, EyeCare America and Celebrity Chefs Want You to Feast Your Eyes on Eye Healthy Foods 3Health News:This Summer, EyeCare America and Celebrity Chefs Want You to Feast Your Eyes on Eye Healthy Foods 4Health News:This Summer, EyeCare America and Celebrity Chefs Want You to Feast Your Eyes on Eye Healthy Foods 5Health News:Aftercad Announces Signup for the 3D Workspace Beta 2Health News:Fighting Multiple Sclerosis One Shirt at a Time 2Health News:Board-Certified Cardiologist Dr. Stephen Sinatra Featured on Searchbodydetox.com 2Health News:Newly Launched Free Choice Foundation Attempts Rescue of Japan's Private Heath Care Network 2Health News:Newly Launched Free Choice Foundation Attempts Rescue of Japan's Private Heath Care Network 3
All purpose, low profile punches with a large square bite....
A straight suture punch with 2.5 mm needle and 2/0 to #1 monofilament suture....
... ratchet design provides fingertip ratchet disengagement allowing ... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ...
... combines solutions for basic requirements with ... diagnostics, integration of the entire digital ... microscope into the hospital's information and ... OR staff.,OPMI Pentero is the first ...
Medicine Products: